Masayuki Ikeda M.D.
Present Address:Department of Pharmaceutical Medicine, Nagasaki University,
School of Medicine
Sakamoto 1-12-4, Nagasaki 852-8523, Japan
Education:
1976-1982 M.D., Tokyo Medical and Dental University, School of Medicine
Position:
1982-1984: Resident in Internal Medicine, Tokyo Medical and Dental
University Hospital , Tokyo , Japan
1984-1986: Fellow in Neurology, Kantoh Teishin Hospital, Tokyo , Japan
1986-88: Researcher in Neuroscience, National Institute of Neuroscience,
National Center of Neurology and Psychiatry, Tokyo , Japan
1988-1990: Neurologist-in-Chief, Asahi General Hospital, Chiba, Japan
1990-1992: Research Scientist, Wellcome Surgical Institute, University
of Glasgow, Glasgow, Scotland
1992-1999: Division Chief, Division of Neurology, Department of Medicine,
Ranzan Institute for the Mentally Retarded, Saitama, & Senior Researcher,
Department of Physiological Chemistry, Graduate School, Tokyo Medical and
Dental University.
1999-June 2003 : Codirector, Department of Clinical Research, National
Saigata Hospital, Niigata, Japan
July 2003-June 2007: Director Medical Reviewer, PMDA (Phamaceuticals
& Medical Devices Agency)
July 2007-September 2008: House Staff, National Chicihbu
Institute for the Mentally Retarded
October 2008- present: Professor of Pharmaceutical Medicine,
Nagasaki University
License:
License of Medical Practice, 1982 Japanese Government,
Fellowship:
Fellow of the Japanese Society of Neurology, 1987,
Fellow of the Japanese Society of Internal Medicine, 1988
Member of ACP, 2000
Publications:
1. Orimo S, Araki M, Ishii H, Ikeda M, Kurosawa T, Arai M, Hiyamuta
E. A case of myopathy with tubular aggregates with increased muscle fiber
sensitivity to caffeine. J Neurol 1987;234:424-426.
2. Ikeda M, Mikuni M, Nishikawa T, Takahashi K. A neurochemical
study of a new mutant mouse presenting myoclonus-like involuntary movement:
a possible model of spontaneous serotonergic hyperactivity. Brain Res 1989;495:337-348.
3. Uchihara T, Ikeda M, Takahashi H, Yoshida S, Tsukagoshi H.
CSF lymphocyte subsets in aseptic meningitis: dual labelling analysis with
flow cytometry. Acta Neurol Scand 1990;81:468-470.
4. Ikeda M, Tsukagoshi H. Encephalopathy due to toluene sniffing,
Report of a case with magnetic resonance imaging. Eur Neurol 1990;30:347-349.
5. Kurumaji A, Ikeda M, Dewar D, McCormac AG, McCulloch J. Effects
of chronic administration of MK-801 upon local cerebral glucose utilization
and ligand binding to the NMDA receptor complex. Brain Res 1991;563:57-65.
6. Uchihara T, Ikeda M, Tsukagoshi H. Recurrent Fisher's syndrmoe
with immunological abnormalities and replicated laterality. Eur Neurol
1991;31:270-272.
7. Ikeda M, Dewar D, McCulloch J. Selective reduction of [125I]-apamin
binding sites in Alzheimer hippocampus, A quantitative autoradiographic
study. Brain Res 1991;567:51-56.
8. Ikeda M, Dewar D, McCulloch J. Preservation of [125I]-galanin
binding sites despite loss of cholinergic neurones in Alzheimer's disease.
Brain Res 1991;568:303-306.
9. Ikeda M, Tsukagoshi H. Monochorea caused by striatal lesion.
Eur Neurol 1991;31:257-258.
10. Ikeda M, Tsukagoshi H. Vogt-Koyanagi-Harada disease presenting
meningoencephalitis, Report of a case with magnetic resonance imaging.
Eur Neurol 1992;32:83-85.
11. Ikeda M, Yoshida S, Tsukagoshi H. Interferon-g in cerebrospinal
fluid without pleocytosis in scrub typhus. J Neurol Sci 1992;109:61-63.
12. Ikeda M, Dewar D, McCulloch J. A correlative study of calcium
channel antagonist binding and local neuropathological features in the
hippocampus in Alzheimer's disease. Brain Res 1992;589:313-319.
13. Ikeda M, Dewar D, McCulloch J. Differential alterations
of multiple ion channel binding sites in the cerebral cortex in Alzheimer's
disease. J Cereb Blood Flow Metab 1993;13:s247.
14. Sato I, Morita I, Kaji K, Ikeda M, Nagao M, Murota S. Reduction
of nitric oxide producing activity associated with aging in cultured human
umbilical vein endothelial cells. Biochem Biophys Res Commun 1993;195:1070-1076.
15. Ikeda M, Dewar D, McCulloch J. High affinity hippocampal
[3H]-glibenclamide binding sites are preserved in Alzheimer's disease.
J Neural Transm [P-D Sect] 1993;5:177-184.
16. Ikeda M, Morita I, Murota S, Sekiguchi F, Yuasa T, Miyatake
T. Cerebellar nitric oxide synthase activity is reduced in nervous and
Purkinje cell degeneration mutants but not in climbing fiber-lesioned mice.
Neurosci Lett 1993;155:148-150.
17. Ikeda M, Dewar D, McCulloch J. Differential alterations
of ion channel binding sites in temporal and occipital regions of the cerebral
cortex in Alzheimer's disease. Brain Res 1993;630:50-56.
18. Ikeda M, Mackay KB, Dewar D, McCulloch J. Differential alterations
in adenosine A1 and k1 opioid receptors in the striatum in Alzheimer's
disease. Brain Res 1993;616:211-217.
19. Ikeda M, Matsui K, Ishihara Y, et al. Cerebellar nitric
oxide synthase, cGMP and motor function in two lines of cerebellar mutant
mice, Staggerer and Wriggle Mouse Sagami. Neurosci Lett 1994;168:65-68.
20. Ikeda M, Takahashi K, Matsunaga T, Tsukagoshi H. Reversible
white matter lesions in a patient with fulminant hepatitis and acute renal
failure. Intern Med 1994;33:360-362.
21. Ikeda M, Takahashi H, Yoshida S. HLA-DR+CD3+ and CD8+ cells
are increased but CD4+CD45RA+ cells are reduced in the peripheral blood
in human scrub typhus. Clin Immunol Immunopathol 1994;72:402-404.
22. Komachi H, Tsuchiya K, Ikeda M, Koike R, Matsunaga T, Ikeda
K. Radiation myelophathy: a clinicopathological study with special reference
tjo correlation between MRI findings and neuropathology. J Neurol Sci 1995;132:228-232.
23. Ikeda M, Dewar D, McCulloch J. Galanin receptor binding
sites in the temporal and the occipital cortex are minimally affected in
Alzheimer's disease. Neurosci Lett 1995;192:37-40.
24. Ikeda M, Sato I, Yuasa T, Miyatake T, Murota S. Nitrite,
nitrate and cGMP in the cerebrospinal fluid in degenerative neurologic
diseases. J Neural Transm [Gen Sect] 1995;100:263-267.
25. Ikeda M, Sato I, Matsunaga T, Takahashi M, Yuasa T, Murota
S. cGMP, nitrite and nitrate in the cerebrospinal fluid in meningitis,
multiple sclerosis and Guillain-Barri syndrome. Intern Med 1995;34:734-737.
26. Himi T, Ikeda M, Sato I, Yuasa T, Murota S. Purkinje cells
express neuronal nitric oxide synthase after methylmercury administration.
Brain Res 1996;718:189-192.
27. Ikeda M, Kanai H, Akaike M, et al. Nitric oxide synthase-containing
neurons in the hippocampus are preserved in trimethyltin intoxication.
Brain Res 1996;712:168-170.
28. Kanai H, Ikeda M, Akaike M, et al. Reaction of NO-synthase
cotaining cells in the rat hippocampus following trimethyltin (TMT) exposure.
In: Kato N, ed. The hippocampus: Function and Clinical Relevances. Amsterdam:
Elsevier, 1997.
29. Ikeda M, Komachi H, Sato I, Himi T, Yuasa T, Murota S. Induction
of neuronal nitric oxide synthase by methylmercury in the cerebellum. J
Neurosci Res 1999;55:352-356.
30. Ikeda M, Komiyama T, Sato I, Himi T, Murota S. Neuronal
nitric oxide synthase is resistant to ethanol. Life Sci 1999;64:1623-1630.
31. Tsuchiya K, Ozawa E, Haga C, Watabiki, S, Ikeda M, Sano
M, Ooe K, Taki K, Ikeda, K. Constant involvement of the Betz cells and
pyramidal tract in multiple system atrophy: a clinicopathological study
of seven autopsy cases. Acta Neuropathol 2000;99: 628-636
32. Suzuki R, Ikeda M, Kami M. Japanese physicians and public
respect. Lancet 2000;356:598-600.
33. Himi T, Ikeda M, Murota S. P2-62 Glutamate uptake inhibitor
L-trans-pyrrolidine 2,4-dicarboxylate induces free radical generation and
glutathione deprivation in cultured hippocampal neurons. Neurochem Res
2000;25:1062-63.
34. Ikeda M and Yoshida S. HIV supression by scrub typhus. Lancet
2000;356:1851
35. Ikeda
M. Iron overload without the C282Y mutation in patients with epilepsy.
J Neurol Neurosurg Psychiat 2001;70:551-3
36. Ikeda M, Arai Y. Longitudinal changes in brain CTscans and
development of dementia in Down's syndrome. Eur Neurol 2002;47:205-208
37. Ikeda
M, MatsunagaT, Irabu N, Yoshida S. Using vital signs to diagnose impaired
consciousness: cross sectional observational study. BMJ 2002;325:800
38.
Himi T, Ikeda M, Yasuhara T, Murota S. Oxidative neuronal
death caused by glutamte uptake inhibition in cultured hippocampal neurons.
J Neurosci Res 2003;71:679-688
39. Himi T, Ikeda M, Yasuhara T, Morita
I. Role of Neuronal Glutamate Transporter in the Cysteine Uptake and Intracellular
Glutathione Levels in Cultured Cortical Neurons. J Neural Transm [Gen Sect]
2003;110: 1337-48
40. Kishi Y, Miyakoshi S, Kami M,
Ikeda M, Katayama
Y, Murashige N, Kusumi E, Yuji K, Kobayashi K, Kato D, Hamaki T, Matsumura
T, Kim S-W, Morinaga , Mori S, Kanemaru M, Hayashi T, Takaue Y, Taniguch
S. Early central nervous system complication following reduced intensity
stem-cell transplantation. Biol Blood Marrow Transplant 2004;10:561-568
41. Ikeda
M. Uses of error. Family bias by proxy. Lancet 2005;365:187
42. Kazuhiko
Kobayashi, Masahiro Kami, Masayuki Ikeda, Yukiko Kishi, Naoko Murashige,
Ryuji Tanosaki, Shin-ichiro Mori1, Yoichi Takaue. Fulminant septicemia
caused by Bacillus cereus following reduced-intensity umbilical cord blood
transplantation. Haematologica 2005;90:ECR06
43. Murashige
N, Kami M, Ikeda M. Aspirin, COX-2, and the Risk of Colorectal
Cancer. N Engl J Med 2007;357: 824.
44. Kondoh
T, Kanno A, Itoh H, Nakashima M, Honda R, Kojima M, Noguchi M, Nakane H,
Nozaki H, Sasaki H, Nagai T, Kosaki R, Kakee N, Okuyama T, Fukuda M, Ikeda
M, Shibata Y, Moriuchi H. Donepezil Significantly Improves Abilities
in Daily Lives of Female Down Syndrome Patients with Severe Cognitive Impairment:
A 24-Week Randomized, Double-Blind, Placebo-Controlled Trial. Int J Psychiatry
Med 2011;41:71-89.
45. Shimazawa
R, Ikeda M. Japan lags behind the UK in neurological drug approvals.
Br J Clin Pharmacol 2011;71:473-475.
46. Ikeda
M. Fulminant form of mitochondrial myopathy, encephalopathy, lactic
acidosis, and stroke-like episodes: A diagnostic challenge. J Med Cases
2011;2(2):87-90.
47. Shimazawa
R, Ikeda M. Delays in neurological drug development in Japan. Internal
Medicine 2011;50:1565-1568.
48. Shimazawa
R, Ikeda M. Medical management of the acute radiation syndrome. Ann Intern
Med 2011;155:135-6.
49. Shimazawa
R, Ikeda M. Drug development against chemical, biological,
radiological, or nuclear agents. Lancet 2011;378:486.
50. FujiwaraT,
Nishimura M, Honda R, Nishiyama T, Nomoto M, Kobayashi N, Ikeda M.
Comparison of peer-led versus professional-led training in basic life support
for medical students. Advances in Medical Education and Practice 2011;2:187–191.
51. Shimazawa R, Kusumi I, Ikeda M. Delays in psychiatric
drug development in Japan. J Clin Pharm Ther (in press)